Cimzia (certolizumab pegol) Rheumatoid Arthritis Market Analysis and Forecast to 2023 offers “Cimzia (certolizumab pegol) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023”global research report on its store.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

UCB’s Cimzia is a pegylated Fab fragment of a humanized anti-TNF IgG molecule, and is indicated for the treatment of adult patients with moderate to severe RA. It is self-administered once every two or four weeks by SC injection. Cimzia dampens the inflammatory process, reducing the rate of progressive joint damage, thus improving physical function. Cimzia is a small antibody, with a mass of about 40kDa (kilodaltons); therefore, it lacks the ability to cross-link, and it also lacks an Fc region. Clinical evidence suggests that Cimzia has an efficacy and safety profile similar to other TNF inhibitors, which may be attributable to its ability to penetrate inflamed joints more efficiently due to its small size. Cimzia is also indicated for Crohn’s disease, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

Complete report is available at .

Scope of The Report:

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cimzia for the top nine countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and China.

Reasons to Buy This Report:

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Cimzia performance.
  • Obtain sales forecast for Cimzia from 2013-2023 in top nine countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia and China).

Order a copy of this report at .

Table of Content for “Cimzia (certolizumab pegol) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023” research report includes:

3 Disease Overview 14

3.1 Etiology and Pathophysiology 14

3.1.1 Etiology 14

3.1.2 Pathophysiology 14

3.2 Symptoms 18

3.3 Prognosis 19

3.4 Quality of Life 19

4 Disease Management 20

4.1 Diagnosis and Treatment Overview 20

4.1.1 Diagnosis 20

4.1.2 Treatment Guidelines 22

4.1.3 Leading Prescribed Drugs for the Treatment of RA 32

4.1.4 Clinical Practice 34

5 Competitive Assessment 39

5.1 Overview 39

6 Cimzia (certolizumab pegol) 41

6.1 Overview 41

6.2 Efficacy 43

6.3 Safety 43

6.4 SWOT Analysis 44

6.5 Forecast 45

1.1 List of Tables

Table 1: Symptoms of RA 18

Table 2: 1987 ACR Diagnostic Criteria for RA 21

Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 22

Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 25

Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 28

Table 6: EULAR 2013 Criteria for RA Remission 29

Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 33

Table 8: Leading Branded Treatments for RA 2014 40

Table 9: Product Profile - Cimzia 42

Table 10: Cimzia SWOT Analysis, 2014 44

Table 11: Global Sales Forecasts ($m) for Cimzia, 2013-2023 45

Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 57

Priced at US $3495 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. (